In an attempt to improve the skin penetration of ketoprofen, various transd
ermal formulations were prepared, and their in vitro skin permeability and
in vivo percutaneous absorption were evaluated. In vitro permeation studies
were performed using a modified Franz cell diffusion system in which perme
ation parameters such as cumulative amount at 8 hr Q(8hr), steady-state flu
x J(ss), or lag time t(L) were determined. In the in vivo percutaneous abso
rption study using the hairless mouse, maximum concentration C-max and area
under the curve at 24 hr AUC(24h) were measured. The optimal transdermal f
ormulation (oleo-hydrogel formulation) of ketoprofen showed a Q(8hr) value
of 227.20 mu g/cm(2), a J(ss) value of 29.61 mu g/cm(2)/hr, and a t(L) valu
e of 0.46 hr. The Q(8hr) and J(ss) values were about 10-fold (p < .01) high
er than those (Q(8hr) = 19.61 mu g/cm(2); J(ss) = 2.66 mu g/cm(2)/hr) from
the K-gel and about 3.5-fold (p < .01) than those (Q(8hr) = 60.00 mu g/cm(2
); J(ss) = 7.99 mu g/cm(2)/hr) of the K-plaster. In the in vivo percutaneou
s absorption, the C-max (6.82 mu g/ml) and AUC(24h) (55.74 mu g . hr/ml) va
lues of the optimal formulation were significantly (p < .01) higher than th
ose of K-gel and K-plaster. The relative bioavailability of the oleo-hydrog
el following transdermal administration in reference to oral administration
was about 37%, and the C-max value (4.73 mu g/cm(2)) in the hypodermis fol
lowing topical administration was much higher than those from the conventio
nal products (C-max of K-gel and K-plaster were 0.92 +/- 0.19 mu g/cm(2) an
d 1.27 +/- 0.37 mu g/cm(2), respectively). These data demonstrate that the
oleo-hydrogel formulation of ketoprofen was more beneficial than convention
al products (K-gel and K-plaster) in enhancing transdermal permeation and s
kin absorption of ketoprofen. Furthermore, there was a good correlation bet
ween in vitro permeation parameters and in vivo percutaneous absorption par
ameters.